findmyKOL
Clinical trialNCT03091192Active, not recruitingPhase 3Interventional

Savolitinib vs. Sunitinib in MET-driven PRCC.

SponsorAstraZenecaEnrollment60CarcinomaCarcinoma, Renal CellEnzyme InhibitorsKidney DiseasesKidney NeoplasmsNeoplasms by Site+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

59 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil
  • Research Site

    Barretos, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Passo Fundo, Brazil

  • Research Site

    Pelotas, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

France
  • Research Site

    Bordeaux, France

  • Research Site

    Vandœuvre-lès-Nancy, France

  • Research Site

    Villejuif, France

Italy
  • Research Site

    Arezzo, Italy

  • Research Site

    Meldola, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Modena, Italy

  • Research Site

    Orbassano, Italy

  • Research Site

    Pavia, Italy

  • Research Site

    Roma, Italy

Russia
  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Murmansk, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Obninsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Volgograd, Russia

South Korea
  • Research Site

    Daejeon, South Korea

  • Research Site

    Goyang-si, South Korea

  • Research Site

    Hwasun-gun, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

19 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Jul 2017
Primary completion
18 Aug 2019
Completion
31 Dec 2026
Last update posted
14 Apr 2026
Registered enrollment
60
Registry id
NCT03091192

Cross-registrations

EU-CTR / CTIS (EudraCT)2016-004108-73

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.